Intended for UK patients and members of the public
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 08 Apr 2025
IAin C.I.3.a - SmPC sections 4.4, 4.5 and 4.8 and PIL have been updated in line with the PRAC recommendation for paracetamol (EPITT No 20105) for high anion gap metabolic acidosis (HAGMA) due to pyroglutamate acidosis.
Last updated on this site: 03 May 2023
Variation description:
Update to SPC section 4.4 and PIL in line with the recommendations following MHRA review of myasthenia gravis (SA 19083871).
Update to PIL in line with the recommendations following MHRA review of CNS depressants (SA 18643283).
Additional update to SPC section 4.2 for 15/500mg strength only to correct strength from ‘500mg/15mg’ to ‘15mg/500mg’ in the renal insufficiency table.
Amends to the PIL in line with the latest QRD template (Version 10.3), and correction of ‘cinacelet’ to ‘cinacalcet’.
PIL sections updated- Heading, Introduction, 2, 3, 4 and 6.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 10 Nov 2023
Description of update: To update sections 4.3, 4.4, 4.5, 4.6, 4.8 and 4.9 in line with the new proposed reference product Solpadol 30mg/500mg Effervescent Tablets (PL 53886/0072, MAH: Opella Healthcare UK Limited). Consequentially, the PIL has been updated. Further editorial updates have been made to the PIL.
PIL sections updated: Introduction, 1, 2, 3, 4 and 6.
Last updated on this site: 10 Nov 2023
Description of update: To update sections 4.3, 4.4, 4.5, 4.6, 4.8 and 4.9 in line with the new proposed reference product Solpadol 30mg/500mg Effervescent Tablets (PL 53886/0072, MAH: Opella Healthcare UK Limited). Consequentially, the PIL has been updated. Further editorial updates have been made to the PIL.
SmPC Sections updated: 4.3, 4.4, 4.5, 4.6, 4.8, 4.9 and 10.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 09 Apr 2025
To update sections 4.4, 4.5 and 4.8 of the SmPC in line with
PRAC recommendation (EPITT No 20105). Consequently, the
PIL has been updated.
In addition; the national text for the driving warning in PIL section 2 has been updated in line with MHRA guidelines, there are editorial updates to SmPC section 4.5 and the PIL and QRD updates to the PIL.
Last updated on this site: 09 Apr 2025
To update sections 4.4, 4.5 and 4.8 of the SmPC in line with
PRAC recommendation (EPITT No 20105). Consequently, the
PIL has been updated.
In addition; the national text for the driving warning in PIL section 2 has been updated in line with MHRA guidelines, there are editorial updates to SmPC section 4.5 and the PIL and QRD updates to the PIL.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 19 May 2023
Variation Description: 1) To update section 4.4 of the SmPC and section 2 of the PIL to include cautionary warning to patients with myasthenia gravis.
2) To update section 4.4 of the SmPC and section 2 of the PIL to highlight the drug interaction between co-codamol and antidepressants.
3) Typographical amendments to the PIL.
SmPC sections updated- 4.4 and 10.
Last updated on this site: 19 May 2023
Variation Description: 1) To update section 4.4 of the SmPC and section 2 of the PIL to include cautionary warning to patients with myasthenia gravis.
2) To update section 4.4 of the SmPC and section 2 of the PIL to highlight the drug interaction between co-codamol and antidepressants.
3) Typographical amendments to the PIL.
PIL sections updated- Heading, 2, 4, 5 and 6.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintDiscontinued Other versions of this medicine may still be available. Information for reference purposes.
Product Documentation
Last updated on this site: 22 Sep 2022
initial upload
Last updated on this site: 22 Sep 2022
initial upload
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 10 Apr 2025
To update sections 4.4, 4.5 and 4.8 of the SmPC to bring in line with the PRAC recommendation (EPITT No 20105) for high anion gap metabolic acidosis (HAGMA) due to pyroglutamate acidosis. Consequently, the PIL has been updated.
Last updated on this site: 10 Apr 2025
To update sections 4.4, 4.5 and 4.8 of the SmPC to bring in line with the PRAC recommendation (EPITT No 20105) for high anion gap metabolic acidosis (HAGMA) due to pyroglutamate acidosis. Consequently, the PIL has been updated.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 17 Apr 2024
Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.
SmPC Sections updated: 4.4, 4.5, 4.9 and 10.
Last updated on this site: 17 Apr 2024
Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.
PIL sections updated: Heading, introduction, 2, 3, 4 and 6.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 03 Oct 2024
To update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC and PIL in line with the reference product Co-Codamol 8/500mg Capsules (PL 42176/0007; MAH: Lucis Pharma Limited) dated 03/06/2024. In addition, editorial updates have been made to PIL.
SmPC section 6.1 and the PIL have been updated to remove "anhydrous" from two excipients, in line with the 9th edition Pharmeuropa and section 4.4 of the SmPC has been updated with excipient Sodium and Sorbitol to be in line with the PIL.
Last updated on this site: 03 Oct 2024
To update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC and PIL in line with the reference product Co-Codamol 8/500mg Capsules (PL 42176/0007; MAH: Lucis Pharma Limited) dated 03/06/2024. In addition, editorial updates have been made to PIL.
SmPC section 6.1 and the PIL have been updated to remove "anhydrous" from two excipients, in line with the 9th edition Pharmeuropa and section 4.4 of the SmPC has been updated with excipient Sodium and Sorbitol to be in line with the PIL.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 16 May 2023
Variation Description: To update section 2 of the PIL following an MHRA review of CNS depressants (SA 18643283). Editorial changes have also been made throughout the PIL.
PIL sections updated – 2, 3, 5 and 6.
Last updated on this site: 08 Apr 2024
Description of update: To update section 4.5 of the SmPC in line with the reference product Co-codamol 8/500 Tablets (PL 17780/0071; MAH: Zentiva Pharma UK Limited) dated 16th June 2023. Additionally, the cartons have been updated with corrected paracetamol warning text.
SmPC Sections updated: 4.5 and 10.
No changes to PIL.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 17 Apr 2024
Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.
PIL sections updated: Heading, introduction, 2, 3, 4 and 6.
Last updated on this site: 17 Apr 2024
Description of update: To update sections 4.4, 4.5 and 4.9 of the SPC to bring in line with the Reference product, Co-codamol 8/500 Effervescent Tablets - PL 17780/0072 (MAH: Zentiva Pharma UK Limited. Consequently, the leaflet (PIL) is being updated.
SmPC Sections updated: 4.4, 4.5, 4.9 and 10.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintA generic drug is a medicine that is developed to be the same as a medicine that has already been authorised, and which is usually branded. Generic medications contain the same active ingredient as the original branded medication and work the same way but may differ in shape or size. Most Accord medications are generic medications.
A biosimilar medication is a biological medication (one whose active substance is made by a living organism) that is highly similar to an already approved biological medicine. These biosimilar medications are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all medicines.
There are two ways to search for a product on the Accord Product Website. The first is to use the search bar at the top of the screen to search by product name or PL number (e.g. 0142/0456). The second way to search for a product is to look at our full list by clicking on “Products” at the top of the screen, or by clicking one of the letter icons at the top of every page.
Search for the relevant product and click on it. Here, you will see all available strengths and their associated documents. Click on one of the links under the “Product Documentation” header to open the document in a new window in your browser. Right click on the document in this new window and select “Print” from the drop-down menu that appears by your cursor.
The controller of your personal data is Accord-UK Ltd, with its registered office at Whiddon Valley, Barnstaple, EX32 8NS, United Kingdom. Your personal data will be processed for the purpose of correspondence, handling your enquiry and/or taking appropriate steps to conclude and perform the contract between the controller and the company you represent. For more information on the processing of personal data, including your rights, please see our Privacy Policy available on our website: https://www.accord-healthcare.com/uk/
A Summary of Product Characteristics (SmPC) is a document describing the properties and the approved conditions of use of a medicine. Summaries of product characteristics form the basis of information for healthcare professionals on how to use the medicine safely and effectively, and are approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) in the EU.
A Patient Information Leaflet (PIL) is a document included in the package of a medication that provides specific information about that medication and its use. It includes information about dose and administration of the medicine, warnings and precautions and potential side effects.
All medicines have both risks and benefits of treatment, it is important to minimise the risks. Some products will have specific activities or materials that companies need to do or provide in order to make the risks of treatment with the medicine as small as possible, these are known as Risk Minimisation Measures or RMMs. Examples of risk minimisation measures could include written guides for patients or healthcare professionals, an alert card for patients or a requirement to ask specific questions if a patient experiences a particular adverse effect of treatment.
Medicines showing this symbol are subject to additional monitoring. This will allow quick identification of new safety information. The black triangle will appear on the Summary of Product Characteristics and the Patient Information Leaflet. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects or report to Accord by clicking on the Report a side effect or a product complaint button, or emailing medinfo@accord-healthcare.com.
As well as Accord products, Accord also sells medications that are licenced by other pharmaceutical companies. If you need information about a product, you may need to check who the marketing authorisation holder is, and this will be on the packaging. You may need to contact the other company for an answer to your query.
All Accord medicinal products have a Product Licence (PL) number. This is unique to each type of medicine and will differ by the strength of each medicine as well. PL numbers are listed under each product on this website. To find your medicine’s PL number, look on the carton or bottle label, as this will have the PL number on it (usually on the back – check beneath the dispensing label if necessary).
For any further assistance, please get in touch.